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ABSTRACT
Introduction Estimating the value of providing effective 
healthcare interventions in a country requires an assessment 
of whether the improvement in health outcomes they offer 
exceeds the improvement in health that would have been 
possible if the resources required had, instead, been made 
available for other healthcare activities in that country. This 
potential alternative use of the same resources represents 
the health opportunity cost of providing the intervention. 
Without such assessments, there is a danger that blanket 
recommendations made by international organisations will 
lead to the adoption of healthcare interventions that are not 
cost effective in some countries, even given existing donor 
mechanisms intended to support their affordability.
Methods We assessed the net health impact to 46 Gavi- 
eligible countries of achieving one of the WHO’s proposed 90-
70-90 targets for cervical cancer elimination, which includes 
90% coverage of human papillomavirus (HPV) vaccination 
among girls by 15 years of age, using published estimates 
of the expected additional benefits and costs in each country 
and estimates of the marginal productivity of each healthcare 
system. We calculated the maximum price each country 
could afford to pay for HPV vaccination to be cost effective by 
assessing the net health impact that would be expected to be 
generated at different potential prices.
Results At Gavi negotiated prices, HPV vaccination offers net 
health benefits across most Gavi- eligible countries included in 
this study. However, if Gavi- eligible countries faced the average 
price faced by non- Gavi eligible countries, providing HPV 
vaccination would result in reduced overall population health in 
most countries.
Conclusion Estimates of the net health impact of providing 
a healthcare intervention can be used to assess the benefit 
(or lack of) to countries of adhering to global guidance, inform 
negotiations with donors, as well as pricing negotiations and 
the value of developing new healthcare interventions.
INTRODUCTION
In 2019, donors funded 27% of healthcare 
provided in low- income countries and 3% in 
lower middle income countries.1 How donors 
make decisions around which interventions 
to fund is unclear.2 Funding may be tied to 
a donor’s strategic mission or aligned to 
international guidance or recommendations. 
Estimating the value of providing effective 
Key questions
What is already known?
 ► Human papillomavirus (HPV) vaccination is considered 
cost effective in almost every country when compared 
against a threshold of 1× gross domestic product (GDP) 
per capita.
 ► GDP per capita- based thresholds are no longer recom-
mended for judging the value for money of healthcare 
interventions.
 ► Country- specific health opportunity costs enable the es-
timation of the impact of an intervention in terms of the 
population net health benefits.
What are the new findings?
 ► Health opportunity costs in Gavi- eligible low- income and 
middle- income countries can be used to estimate the 
scale of the expected net impact on population health 
of HPV vaccination.
 ► At Gavi negotiated prices, HPV vaccination offers posi-
tive net health benefits in most of the Gavi- eligible coun-
tries included in this study.
 ► If Gavi- eligible countries faced the same price as non- 
Gavi eligible countries, providing HPV vaccination would 
improve overall population health in 13 countries and re-
duce overall population health in 33 countries imposing 
a net burden of 38 million disability- adjusted life years.
What do the new findings imply?
 ► Gavi’s negotiations on behalf of countries eligible for its 
support have succeeded in making adhering to the WHO 
guidance around HPV vaccination a beneficial aim for 
most countries.
 ► Determining prices using these methods, which account 
for country- specific health opportunity costs, offers an 
opportunity to ensure that all countries can benefit from 
adopting HPV vaccination or other recommendations 
made by global bodies.
 ► Assessing the likely scale and distribution of the impact 
of potential new interventions on net population health, 
at a particular price, are valuable for informing priorities 
in developing new healthcare interventions.
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interventions in a country—including vaccines, drugs, 
and diagnostics, as well as prioritising the development 
of new ones—requires an assessment of whether the 
improvement in health outcomes they offer exceeds the 
improvement in health that would have been possible if 
the resources required had, instead, been made available 
for other healthcare activities in that country. This poten-
tial alternative use of the same resources represents the 
health opportunity cost of providing the intervention. 
Without such assessments, there is a danger that blanket 
recommendations made by international organisations 
will lead to the adoption of healthcare interventions 
that are not cost effective in some countries, even given 
existing donor mechanisms intended to support their 
affordability.
To assess the health opportunity cost of providing an 
intervention in a given country, an assessment of the 
health effects if the additional resources required had, 
instead, been made available to other healthcare activi-
ties is needed. This requires country- specific estimates of 
the health effects of changes in healthcare expenditure. 
Such estimates are now available for a limited number 
of high- income countries based on within- country data 
and a wider range of high- income as well as low-/middle- 
income countries (LMICs) based on country- level data. 
These are typically reported as a cost per quality- adjusted 
life year (QALY) gained or disability- adjusted life years 
(DALY) averted.3–13
Comparing the additional cost per QALY gained or 
DALY averted by an intervention with an estimate of 
cost per QALY gained or DALY averted that reflects 
health opportunity costs enables a binary assessment of 
whether the intervention produces health at a better 
(worse) rate than interventions already funded by the 
healthcare system (HCS)—that is, is below (above) the 
estimate of cost per QALY gained or DALY averted that 
reflects health opportunity costs. However, binary assess-
ments such as these obscure valuable information about 
the scale of the net benefits (or losses) associated with 
providing or developing an intervention, and other 
local context- specific important criteria of affordability, 
budget impact, fairness and feasibility.14 This is partic-
ularly important when assessments of value are made 
across countries; an intervention may be expected to 
generate a net benefit in some, but a net loss in others.
Explicit consideration of the trade- offs between, for 
example, providing an intervention in all versus some 
countries requires quantifying the scale of the benefits 
(or losses) across countries. The scale of potential net 
benefits (or losses) associated with providing an inter-
vention in a country can be measured by the net health 
impact of the intervention: that is the health that is gener-
ated by it minus its health opportunity cost. The health 
opportunity costs associated with additional healthcare 
expenditure in each HCS differs depending on for 
example, the budget for healthcare, efficiency of current 
spending, demographic structure and epidemiology. As 
such, the health opportunity cost of providing the same 
intervention at the same price, even to the same sized 
population, will be different in different HCS.
To illustrate this, we assess the net health impact to 
countries of achieving one of the WHO’s proposed 
90-70-90 targets for cervical cancer elimination, which 
includes 90% coverage of human papillomavirus (HPV) 
vaccination among girls by 15 years of age.15 This paper 
shows how estimates of the expected additional benefits 
and costs of HPV vaccination and health opportunity 
costs can be used to assess the expected net health impact 
for each country and across countries associated with 
adhering to the WHO guidance. We also show how these 
metrics can inform pricing negotiations (eg, between 
Gavi, the Vaccine Alliance (hereafter Gavi) and manufac-
turers), and discuss how they may be used to inform the 
development of new healthcare interventions.
METHODS
Assessing the expected net health impact for each country 
and across countries requires data on the additional costs 
and benefits of HPV vaccination for each country and an 
estimate of the health opportunity costs faced by each 
countries’ HCS. We consider countries that were Gavi 
eligible in 2019 (the most recent year for which a list of 
eligible countries is publicly available).16 Estimates of the 
additional health benefits of HPV vaccination over the 
period 2020–2029 come from the Papillomavirus Rapid 
Interface for Modelling and Economics (PRIME) model 
developed by Jit et al (2014) and recently updated by 
Abbas et al (2020).17 18 PRIME assumes lifelong vaccine 
protection, no indirect (herd) effects and no changes to 
screening programmes.
The additional (ie, net) cost of vaccination ( ∆Ci ) is 
made up of the cost of procurement ( ∆C
P
i  ), which is a 
function of the per dose procurement price and number 
of doses, the cost of delivering the vaccine in a country 
( ∆C
D
i  ), and the cost savings that result from cervical 
cancers averted ( ∆C
C
i  )
 ∆Ci = ∆C
p
i + ∆CDi −∆CCi  (1)
The market price for HPV vaccine doses in countries not 
eligible for Gavi support is on average US$25 per dose.19 
Below private market rate procurement prices were 
negotiated by Gavi with HPV vaccine manufacturers, 
enabling Gavi eligible countries to purchase vaccines 
through United Nations organisations at US$4.50 per 
dose.20 21 Countries purchase a share of the vaccines 
provided while Gavi purchases the remainder. The share 
funded by Gavi is based on the Gavi cofinancing mecha-
nism depending on the funding phase the country is in.22 
We assume two doses per vaccinated girl in line with the 
WHO recommended schedule for HPV vaccination, and 
that the per dose price remains constant in real terms 
over the period 2020–2029.23 Delivery costs are assumed 
to be US$1.76 per dose (2019 US$) for low- income 
countries and US$3.87 per dose (2019 US$) for middle- 
income countries24 (originally in 2013 US$, scaled up 
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using gross domestic product (GDP) deflator 2011 Q1 to 
2019 Q3 for USA from the US Federal Reserve https:// 
fred. stlouisfed. org/ series/ GDPDEF). In combination 
with published estimates of the health opportunity costs 
faced by different HCS from Ochalek et al (2018), the 
scale of the net health impact of HPV vaccination by 
HCS, measured in DALYs averted (net DALYs averted, 
 NDAi , where the  i subscript denotes each HCS) can be 
estimated for each HCS. No estimates of the health 
opportunity costs associated with additional healthcare 
expenditure are available for 12 countries, limiting our 
analysis to 46 Gavi- eligible countries.
 NDAi = ∆DALYsi −
∆Ci
ki  (2)
Net DALYs averted (NDA) for a given HCS is the differ-
ence between DALYs averted by an intervention ( DALYsi
 ) and DALYs that could have been averted with the addi-
tional HCS resources required to implement it ( 
∆Ci
ki  ) (net 
of any additional cost savings), where  ki  is the country- 
specific estimate of health opportunity cost to avert a 
single DALY. Note that if the net effect of the interven-
tion saves HCS costs, that is,  ∆Ci < 0 , then the net DALYs 
averted is the DALYs averted by the intervention plus the 
additional DALYs that can also be averted with the cost 
savings offered.
The scale of the value of the impact can also be 
reported in terms of the amount of additional healthcare 
resources which would be required to deliver similar net 
health impacts (net dollar value,  N$Vi ).
 N$Vi = ki ∗∆DALYsi −∆Ci (3)
The aggregate net effects of providing the HPV vaccine 
in a group of countries (eg, all countries in a given 
income category) can be calculated by summing the esti-
mated net health impact or net dollar value by HCS. For 
example, where HPV is provided in a group,  g , of N HCS, 
these can be calculated as follows:
 
NDAg =
N∑
i=1
∆DALYsi − ∆Ciki  
(4)
 
N$Vg =
N∑
i=1
ki ∗∆DALYsi −∆Ci
 
(5)
An estimate of the health opportunity costs faced by the 
HCS also enables the calculation of the maximum per 
dose procurement price, which is calculated by dividing 
the maximum procurement cost ( CPi ∗ ) by the number of 
required doses (two doses are required for each person 
in the cohort), that each HCS could afford to pay for 
HPV vaccine to ensure that the health lost from the 
money required to fund it is not greater than the benefit 
it offers (ie, the cost at which the net dollar value to the 
HCS would be zero).
 ∆C
P∗
i = ∆DALYsi ∗ ki −∆CDi + ∆CCi  (6)
This can be used to inform pricing negotiations 
between Gavi and manufacturers in a way that ensures 
that global access could be provided with no net losses 
for any HCS.
We illustrate how these assessments can be used to 
inform global guidance or recommendations and pricing 
negotiations by assessing four potential policy options:
1. Achieving the WHO recommendation of 90% cov-
erage of HPV vaccination in Gavi- eligible countries 
at the average market per dose procurement prices 
(US$25 per dose).
2. Informing country- specific per dose procurement 
prices that would ensure that HPV vaccination gener-
ates a net health benefit in each Gavi- eligible country.
3. Informing per dose procurement prices for country 
groups (ie, low- income and lower middle income) 
that would ensure that HPV vaccination generates a 
net health benefit in each Gavi- eligible country.
4. Achieving the WHO recommendation of 90% cover-
age of HPV vaccination in all Gavi- eligible countries 
at current Gavi- negotiated per dose procurement pric-
es (US$4.50 per dose) first assuming current levels of 
support for procurement (option 4a) and second, as-
suming no procurement support (option 4b).
Policy option 1 reflects the implementation of blanket 
recommendations for providing an intervention for an 
entire set of countries (see, eg, World Health Organ-
ization, 2020).25 Policy option 4 reflects the practice of 
negotiating prices to support countries in complying with 
recommendations. Policy options 2 and 3 reflect poten-
tial methods for determining prices.
While all Gavi funded countries face the same per 
dose price (US$4.50) for HPV vaccines, most Gavi- 
funded countries pay for only a portion of the vaccines 
they purchase while the remainder are funded by Gavi. 
The share funded by Gavi is based on a cofinancing 
mechanism, and differs for each country depending on 
the funding phase the country is in and its per capita 
income.22 In the first instance, we assume current Gavi- 
negotiated per dose procurement prices and with 
current levels of support (policy option 4a). Since data 
on the proportion of vaccines purchased by Gavi are not 
publicly available, we have calculated them based on the 
number of years a country has been a Gavi funding recip-
ient and the countries’ gross national income (GNI) per 
capita in each of those years (see online supplemental 
appendix 1). Second, we assess this scenario assuming 
that countries pay 100% of the vaccine procurement 
costs (ie, US$4.50 per dose; which we term policy option 
4b). Delivery costs are the same for each option and are 
current delivery costs.
We also undertake sensitivity analyses around discount 
rates and the estimates of the marginal productivity of 
HCSs used. Global guidance recommends that where 
country guidance is lacking either 0% for health benefits 
and 3% for costs or 3% for both are used as discount 
rates.26–28 Following common practice, our base case for 
each policy option applies a discount rate of 3% to both 
costs and benefits,29 30 and we assess the results where 
0% is applied to health benefits in sensitivity analysis. 
Our base case uses the central estimate of health oppor-
tunity cost for each country from Ochalek et al.31 We 
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also assess each policy option using the minimum and 
maximum estimates of cost per DALY for each country 
from Ochalek et al (2018) as a sensitivity analysis.31
The total net health impact across all countries for 
the first policy option, where HPV vaccination is imple-
mented in all countries at current market prices, is calcu-
lating by aggregating the NDA for each country from 
equation 2.
The second policy option entails calculating the 
maximum price each HCS could afford to pay for HPV 
vaccination to be a cost- effective use of resources in that 
HCS if it is not already cost effective at average market 
price (US$25 per dose). This is calculated by deter-
mining the maximum total vaccination procurement cost 
a country can afford to pay, which is the monetary value 
of the expected health gains of HPV vaccination net of 
the difference between the delivery costs and cancer 
treatment costs averted (as set forth in equation 6).
The third policy option, to set a price by HCS group 
(eg, income group) rather than by country, is also 
informed by equation 6, but the lowest maximum price 
affordable from among a group of countries is applied to 
all countries in the group.
The fourth policy option reflects the total net health 
impact of implementing HPV vaccination in all countries 
at Gavi negotiated prices and with current levels of Gavi 
support (policy option 4a) or at Gavi negotiated prices 
without procurement support (policy option 4b) and is 
calculated by aggregating the NDA for each country from 
equation 2.
RESULTS
Figure 1A plots the health gains from the vaccine against 
the health opportunity cost for each country of achieving 
the WHO recommendation of 90% coverage of HPV 
vaccination in all Gavi- eligible countries at average 
market per dose procurement prices (US$25 per dose) 
and given current delivery costs (policy option 1). The 
diagonal line indicates zero net health impact, and 
(black) points that fall above it refer to countries which 
have a positive net health impact while (grey) points that 
fall below it refer to countries which have a negative net 
health impact.
What is evident is that at this price HPV vaccine results 
in net health losses in most countries. More countries 
are below the zero net impact line than above it. The 
distance between a point above (below) the line and the 
line is the net health gain (loss) that would result from 
providing the intervention. There are net health gains 
in some countries (totalling 2 million DALYs averted); 
however, these are offset by the net health losses in others 
(totalling −40 million DALYs averted (see table 1 column 
1).
If HPV vaccination were provided only in those coun-
tries where it does not reduce overall net health at 
current average market price, it would be implemented 
in only 2 of 22 low- income countries and 11 of 24 lower 
middle income countries where it would generate a net 
health benefit. While there is a clear benefit to this policy 
option (ie, it would ensure that overall health across the 
countries increases as a result of the recommendation, 
and health is not reduced anywhere), it unlikely to be 
politically feasible or appealing to restrict access in this 
way. It may also not be seen as equitable to provide vacci-
nation only to countries that can afford to pay a uniform 
price for it.
Pricing arrangements that ensure that HPV vaccine 
generates a net health benefit for each country requires 
calculating the per dose price at which HPV vaccination 
would be cost effective in each HCS for which it is not at 
US$25 per dose (policy option 2). This is visualised in 
figure 1B, where all of the countries that previously had 
negative net health impact (as denoted by grey points in 
figure 1A) are now on the zero net impact line.
Table 2 reports the per dose price at which HPV vacci-
nation would be cost effective in each HCS for which it 
Figure 1 (A) Net health impact in Gavi- eligible countries. (B) Net health impact in Gavi- eligible countries after country- specific 
subsidies. DALYs, disability- adjusted life years; HPV, human papillomavirus; MICs, middle- income countries.
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Table 2 Country- specific and income group- specific price reductions required
Country Income group
Per dose price 
reduction 
required (2019 
US$)
Cohort size
(1000s)
Total reduction using 
country- specific price 
(1000s, 2019 US$, 
option 2)
Total reduction using country 
income group price (1000s, 
US$−1 for low- income countries, 
US$0 for lower middle income 
countries, 2019 US, option 3)
Benin Low 18 1567 57 749 80 661
Burkina Faso Low 10 2851 57 074 146 744
Burundi Low 9 1703 31 075 87 647
Chad Low 21 2372 101 129 122 104
Democratic Republic of 
the Congo
Low 23 12 881 582 915 663 039
Eritrea Low 22 425 18 430 21 877
Ethiopia Low 17 14 104 491 992 725 995
Gambia Low 9 332 5981 17 090
Guinea Low 14 1744 48 351 89 790
Guinea Bissau Low 22 256 11 104 13 159
Haiti Low 21 1088 45 173 55 990
Madagascar Low 15 3434 105 294 176 781
Malawi Low 0 2510 0 129 186
Mali Low 19 2927 108 948 150 676
Mozambique Low 2 4319 20 123 222 326
Nepal Low 13 2418 62 126 124 454
Niger Low 24 3811 183 674 196 160
Rwanda Low 8 1587 25 035 81 666
Sierra Leone Low 24 978 46 162 50 321
Togo Low 21 1034 42 623 53 232
Uganda Low 8 6512 108 355 335 200
Yemen Low 26 3515 180 923 180 923
Bangladesh Lower middle 23 12 719 592 799 645 928
Cambodia Lower middle 20 1549 61 602 78 677
Cameroon Lower middle 17 3447 119 244 175 050
Comoros Lower middle 0 103 0 5236
Côte d'Ivoire Lower middle 16 3418 110 006 173 553
Ghana Lower middle 3 3511 23 785 178 321
India Lower middle 18 100 082 3 511 214 5 082 526
Kenya Lower middle 0 6225 0 316 137
Kyrgyzstan Lower middle 0 669 0 33 951
Lesotho Lower middle 0 205 0 10 408
Mauritania Lower middle 7 573 7837 29 105
Nicaragua Lower middle 0 570 0 28 958
Nigeria Lower middle 17 27 327 922 743 1 387 758
Pakistan Lower middle 25 22 940 1 164 963 1 164 963
Republic of Congo Lower middle 0 705 0 35 787
Republic of Sudan Lower middle 23 5322 244785 270266
Senegal Lower middle 0 2219 0 112 695
South Sudan Lower middle 9 1399 24665 71023
Tajikistan Lower middle 23 1125 51 199 57 107
Tanzania Lower middle 0 8087 0 410 661
Uzbekistan Lower middle 5 2929 29 386 148 753
Vietnam Lower middle 8 6530 99 216 331 607
Continued
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is not at US$25 per dose. That is the maximum that the 
country could afford to pay per dose for HPV vaccination 
to generate zero net benefit (ie, no net loss in overall 
population health, but also no net benefit). Among 
countries where a price reduction is required, the price 
reduction ranges from US$2 to US$26 (2019 US). If the 
vaccine manufacturer and/or a global donor were to 
fund the difference for both doses for all eligible girls 
for each country, it would cost US$9.3 billion (2019 US). 
The same money could avert 49 million DALYs if spent 
on existing interventions in these countries instead.
Alternatively, prices might be negotiated by country 
groups, such as income category if it is not possible to 
have country- specific pricing arrangements (policy 
option 3). In order to ensure providing HPV vaccination 
in all countries within an income group (or any group for 
that matter) generates a net benefit, or at minimum no 
net loss in overall population health, requires applying 
the lowest price required for HPV vaccination to be cost 
effective in any of the countries in the group to all coun-
tries in the group. This would be US$−1 per dose (2019 
US) in low- income countries and US$0 per dose (2019 
US) in lower middle- income countries. If the manufac-
turer and/or a global donor were to fund the difference 
for each country, it would cost US$14.7 billion (2019 
US). More net health benefits would be generated across 
countries than from option 2; however, the same money 
could avert 70 million DALYs if spent on existing inter-
ventions in these countries instead.
The net health impact and net monetary impact of 
achieving the WHO recommendation of 90% coverage of 
HPV vaccination in all Gavi- eligible countries at current 
Gavi- negotiated prices (US$4.50 per dose, 2019 US), with 
current delivery costs and existing levels of Gavi procure-
ment support, where many countries pay below US$4.50 
per dose, are presented in table 1 (columns 3 and 4). This 
represents existing policy (policy option 4a) and offers 
positive net health impact for all but three countries, 
implying that at current prices and levels of Gavi support 
HPV vaccination generates a health benefit over and 
above any loss incurred as a result of the money required 
to fund it not being available to fund other healthcare 
interventions for most countries. Without the Gavi 
procurement support (ie, at a per dose price of US$4.50 
(2019 US) for all countries, option 4b), HPV vaccination 
generates a net health loss in eight more countries than 
it would with the Gavi procurement support (see table 1 
columns 5 and 6).
Sensitivity analyses
Our analysis used a discount rate of 3% for costs and 
benefits following common practice. While this is in line 
with the WHO guidance, the guidance also recommends 
a sensitivity analysis where health is undiscounted but 
costs are discounted at 3%.26 The resulting net health 
impact estimates for this sensitivity analysis are reported 
against the base case in online supplemental appendix 
table 1 and the price reductions required are reported 
against the base case in online supplemental appendix 
table 2. The health benefits of HPV vaccination often 
occur in future years (eg, cancer cases are averted up to 
decades after the vaccine has been administered). Since 
greater weight is attached to future health outcomes 
when they are undiscounted, discounting the health 
benefits from HPV vaccination has the effect of reducing 
their net present value. Therefore, HPV vaccination 
appears better value when no discounting is applied to 
health benefits. The per dose price reduction required 
in order for HPV vaccination to generate zero net benefit 
(ie, no net loss in overall population health, but also no 
net benefit) in countries where it generates a net loss 
at average market price are also lower (and more often 
zero or not required at all) than when a 3% discount 
rate is used for health benefits. If country- specific pricing 
were possible, the total price reduction required (ie, for 
all doses for all eligible girls across all countries where 
a price required is required) would be less than a third 
of that required when a 3% discount rate is applied to 
health benefits. Where country income- group pricing is 
applied, the difference in funding required is lower at 
US$11.6 billion (compared with US$14.7 billion when a 
3% discount rate is applied to health benefits). The price 
for low- income countries would be US$2 per dose and 
for lower middle income countries it would be US$6 per 
dose (2019 US$).
Country Income group
Per dose price 
reduction 
required (2019 
US$)
Cohort size
(1000s)
Total reduction using 
country- specific price 
(1000s, 2019 US$, 
option 2)
Total reduction using country 
income group price (1000s, 
US$−1 for low- income countries, 
US$0 for lower middle income 
countries, 2019 US, option 3)
Zambia Lower middle 0 2506 0 127 288
Zimbabwe Lower middle 0 1911 0 97 035
Low- income countries     2 334 238 3 725 020
Lower middle income 
countries
    6 963 445 10 972 795
All countries     9 297 682 14 697 815
Table 2 Continued
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Our analysis uses the central estimate of the marginal 
productivity of each HCS from the range estimated by 
Ochalek et al.31 As a sensitivity analysis, we use the minimum 
and maximum from the ranges for each country. Using 
the minimum (maximum) estimate for each country will 
tell us the maximum (minimum) health opportunity cost 
expected from adopting HPV vaccination and therefore 
lowest (highest) estimate of net health benefit from it for 
each country. The results of this sensitivity analysis are 
reported in online supplementary appendix tables 3 and 
4. Using the minimum or maximum makes little overall 
difference to the number of countries for which HPV 
vaccination would be expected to generate a net health 
benefit. Among low- income countries, at market price 
(US$25 per dose) one fewer low- income country would 
be estimated to have a net health benefit from adopting 
HPV vaccination when the minimum estimate of the 
marginal productivity of each HCS is used. Results do not 
change when current per dose procurement prices are 
used (as in option 4a), but when the price is US$4.50 per 
dose (option 4b) three additional low- income countries 
would expect a net health benefit when the maximum 
estimate of the marginal productivity of each HCS is used 
while one fewer would expect a net health benefit when 
the minimum is used (compared with the central esti-
mate). Among lower middle income countries adopting 
HPV vaccination would be estimated to generate a net 
health benefit in one fewer (more) country when the 
minimum (maximum) estimate of the marginal produc-
tivity of each HCS is used at market price (US$25 per 
dose), but results do not change when current per dose 
procurement prices (as in policy option 4a) or US$4.50 
per dose (policy option 4b) are used. Even when intro-
ducing HPV vaccination would result in net health 
benefit for the same number of countries regardless of 
whether the minimum, central or maximum estimate 
is used, the magnitude of the net health benefit differs. 
The estimated net health benefits (losses) are greatest 
(lowest) when using the maximum estimate of health 
opportunity cost from the range. The price reduction 
required for HPV vaccination to generate a net health 
benefit in all countries is higher (lower) when using the 
minimum (maximum) estimate of health opportunity 
costs. When the minimum estimate is used the per dose 
price reduction required in both low- income and lower 
middle income countries is US$26 (2019 US; ie, the 
maximum that the country that can least afford to adopt 
HPV vaccination can afford to pay is US$−1 per dose). 
When the maximum estimates of health opportunity cost 
are used, the price reductions required for low- income 
and lower middle- income countries are US$26 and 
US$25 (2019 US), respectively, which is the same as the 
base case (ie, when the central estimate is used). When 
country- specific pricing is used (as in policy option 2), 
this amounts to a total of US$8.6 billion to US$9.9 billion 
in funding required when the maximum and minimum 
estimates are used, respectively. When country income 
group pricing is used (as in policy option 3), this amounts 
to a total of US$14.5 billion to US$14.8 billion in funding 
required when the maximum and minimum estimates 
are used, respectively.
DISCUSSION
The analysis undertaken enables an assessment of blanket 
recommendations (in order to, eg, inform whether, at 
current prices, they would be expected to improve health 
in all countries); an assessment of the price reduction (if 
any) required for a healthcare intervention to generate 
at minimum no net health loss; and the value of devel-
oping new healthcare interventions.
Previous analyses have used a GDP per capita threshold 
to judge the cost effectiveness of adopting HPV vaccina-
tion and eliminating cervical cancer.17 18 32 The GDP per 
capita threshold originates from human capital argu-
ments made by the WHO Commission on Macroeco-
nomics and Health around the value of a year of life.33 
However, WHO no longer recommends it for country 
evaluations on the basis that it may not reflect country 
priorities and decision- making processes.14 Estimates of 
the marginal productivity of HCSs reflect health oppor-
tunity cost and tend to be lower than GDP per capita, 
and so using a GDP per capita threshold to make deci-
sions can lead to net health losses.8 31 Indeed, in practice, 
low- income countries' actual decisions to introduce HPV 
vaccination, or not, reveal an implicit cost- effectiveness 
threshold of 30%–35% of GDP per capita.34 Reassuringly, 
our results show that HPV vaccination remains cost effec-
tive for most countries at current Gavi negotiated prices 
when a threshold that reflects the health opportunity 
cost faced by the country is used (rather than human 
capital arguments about the value of health spending). 
Although there is uncertainty around existing estimates 
of the marginal productivity of HCSs, using the minimum 
or maximum from the range of estimates from Ochalek et 
al (2018) has little impact on the results.
A blanket recommendation to introduce HPV vaccina-
tion in LMICs would result in net health losses in most 
countries in the absence of Gavi support. This was anal-
ysed under the assumption that these countries would 
face the average market price faced by countries not 
eligible for Gavi support. Manufacturers might be able 
to price discriminate (ie, using tiered pricing policy), 
reducing prices for these countries. However, there is no 
guarantee that in the absence of pooled procurement and 
market shaping efforts by organisations like Gavi lower- 
income countries would pay lower prices.35 The extent 
to which prices would be lower than the average market 
price among high- income countries in the absence of 
Gavi support is unclear but would result in better net 
health impacts, while higher prices would result in worse 
net health impacts. It is worth noting that our estimate 
for policy option 1 being conservative or optimistic has 
no implications for comparisons between policy options 
2, 3, 4a and 4b.
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The current reality of vaccine procurement prices 
paid by countries likely falls somewhere between policy 
options 2 and 4. Policy option 4 assumed all countries 
pay S$4.50 per dose or less (as countries purchase a 
share of the vaccines provided while Gavi purchases the 
remainder). The share funded by Gavi is based on the 
Gavi cofinancing mechanism depending on the funding 
phase the country is in (based on country income level 
and years of funding) rather than reflecting health oppor-
tunity costs as in policy option 2.22 However, in practice, 
countries may not meet their cofinancing requirements. 
Gavi funding a greater proportion of vaccines would 
have the effect of reducing the per dose price below the 
prices used in 4a, and all else the same the vaccine would 
generate a more positive net impact in those countries. 
Determining prices using a more systematic method of 
accounting for opportunity costs, as illustrated in policy 
option 2, offers an opportunity to ensure that countries 
that do not benefit from adopting HPV vaccination 
at current prices would be able to introduce it without 
facing a reduction in population health. Future research 
could seek to establish the best way for donors to support 
the affordability of interventions, which would require 
information on the opportunity cost of donor financial 
support and the loss of revenue for the manufacturers 
of vaccine, in addition to the transaction costs associated 
with implementing donor support mechanisms.
This type of analysis can also help to inform the value 
of developing a new healthcare intervention that does 
not yet exist. For example, the Bill and Melinda Gates 
Foundation funds the development of new healthcare 
interventions targeted towards the leading causes of 
death and disability in LMICs. While a more uncertain 
prospect at this earlier stage, estimating the price at 
which a healthcare intervention would have a positive 
net health impact in each HCS (as in policy option 2) 
can help to inform whether it should be considered 
for development by the foundation, through compar-
ison with the cost of the intervention to the provider. 
Using the expected net health impact of different poten-
tial healthcare interventions (and how this is distrib-
uted across countries) to rank potential investments 
would ensure that new healthcare interventions which 
are likely to generate the greatest health gains offered 
at affordable prices are prioritised over others. Value 
of information analysis provides a means to prioritise 
future research to resolve uncertainties with the new 
healthcare interventions under consideration for devel-
opment. However, the development of a new healthcare 
intervention may be seen to address multiple objectives 
in addition to improving overall population health. 
This framework could be extended to incorporate 
other objectives, such as equity, following, for example, 
extended or distributional cost- effectiveness analysis 
methods. In fact, prioritisation decisions for both vaccine 
research and development (eg, the Vaccine Innovation 
Prioritisation Strategy) and financing for adoption (eg, 
the Gavi Investment Strategy) use a kind of multicriteria 
decision analysis that considers cost effectiveness along-
side multiple other criteria.36 37
Equity concerns may also be relevant for interventions 
for which a net health benefit is generated in some, but 
not all, countries in which it is recommended. The benefit 
associated with providing HPV vaccination in some coun-
tries may outweigh the losses in other countries if, for 
example, to reflect equity being another objective in 
decision- making more weight is given to gains in low- 
income countries and this is where the bulk of the gains 
are. Assessing the net health impact of providing a health-
care intervention for each country enables decision- 
makers to be explicit about the trade- offs being made if, 
for example, net health losses were incurred in some low- 
income countries but no lower middle income countries. 
If more weight was put on outcomes in low- income coun-
tries, a blanket recommendation of providing the health-
care intervention would appear to be less favourable as 
policy choice if the price was the same in all countries as 
this is where a disproportionately larger amount of the 
overall losses in net health would be incurred.
The results are sensitive to the discount rate used. The 
WHO recommends initially using the discount rate used 
in the country, and where national guidelines do not 
exist recommends two scenarios: our base case (ie, 3% 
discounting for both health and consumption) and sensi-
tivity analysis (ie, 3% and 0% discounting for consump-
tion and health, respectively).26 However, application of 
the same discount rates for all countries is unlikely to be 
appropriate. Where the objective is improving popula-
tion health, for example, the appropriate discount rate 
for health for each country should depend on the rate at 
which the principal can borrow and save and the expected 
growth in the marginal productivity of the HCS38 39—
both of which would be expected to vary by country. To 
date, there are no data on the expected growth in the 
marginal productivity of the HCS, and this should be a 
priority for future research.
CONCLUSION
This paper illustrates how estimates of the net health 
impact or, equivalently, net monetary value of providing 
a healthcare intervention can be used to estimate the 
expected effect to overall population health in a country 
of adhering to global guidance and inform negotiations 
with donors, as well as informing pricing negotiations 
and the value of developing new healthcare interven-
tions. At Gavi negotiated prices, HPV vaccination gener-
ates net health benefits across nearly all Gavi- eligible 
countries included in this study. However, if Gavi- eligible 
countries faced the same price as non- Gavi eligible coun-
tries, providing HPV vaccination would reduce overall 
population health in all but two low- income and nearly 
half of lower middle income countries and impose a net 
DALY burden of 38 million DALYs globally. This suggests 
that Gavi’s negotiations on behalf of countries eligible 
for its support have succeeded in making adhering to the 
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WHO guidance around HPV vaccination a worthy aim 
for most countries. Assessing the likely scale and distribu-
tion of the impact of potential new interventions on net 
population health, at a particular price, can also inform 
priorities in developing new technologies. The maximum 
price each country could afford to pay for HPV vaccina-
tion to be cost effective can be calculated as can the net 
health benefit that would be expected to be generated at 
different potential prices. Determining prices using these 
methods, which account for country- specific opportunity 
costs, offers an opportunity to ensure that all countries 
can benefit from adopting HPV vaccination or other 
recommendations made by global bodies. Finally, the 
methods used here can be applied to assess the value 
of developing a new technology. It will also depend on 
not only the expected costs and benefits of the new tech-
nology for each country in which it may be implemented, 
but as well the likely health opportunity costs in those 
countries.
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